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Promoter considerations in the design
of lentiviral vectors for use in treating
lysosomal storage diseases
Estera Rintz,1,2 Takashi Higuchi,3 Hiroshi Kobayashi,3 Deni S. Galileo,4 Grzegorz Wegrzyn,1
and Shunji Tomatsu2,4,5,6
1Department

of Molecular Biology, Faculty of Biology, University of Gdansk, Wita Stwosza, 59, 80-308 Gdansk, Poland; 2Nemours/Alfred I. duPont Hospital for Children,

1600 Rockland Road, Wilmington, DE 19803, USA; 3Division of Gene Therapy, Research Center for Medical Sciences, The Jikei University School of Medicine, 3
Chome-25-8 Nishishinbashi, Minato City, Tokyo 105-8461, Japan; 4Department of Biological Sciences, University of Delaware, 118 Wolf Hall, Newark, DE 19716,
USA; 5Department of Pediatrics, Gifu University, Gifu, Yanagido 501-1193, Japan; 6Department of Pediatrics, Thomas Jefferson University, 901 Walnut Street,
Philadelphia, PA 19107, USA

More than 50 lysosomal storage diseases (LSDs) are associated
with lysosomal dysfunctions with the frequency of 1:5,000 live
births. As a result of missing enzyme activity, the lysosome
dysfunction accumulates undegraded or partially degraded
molecules, affecting the entire body. Most of them are lifethreatening diseases where patients could die within the ﬁrst
or second decade of life. Approximately 20 LSDs have the
approved treatments, which do not provide the cure for the disorder. Therefore, the delivery of missing genes through gene
therapy is a promising approach for LSDs. Over the years,
ex vivo lentiviral-mediated gene therapy for LSDs has been approached using different strategies. Several clinical trials for
LSDs are under investigation.Ex vivo lentiviral-mediated gene
therapy needs optimization in dose, time of delivery, and promoter-driven expression. Choosing suitable promoters seems
to be one of the important factors for the effective expression
of the dysfunctional enzyme. This review summarizes the
research on therapy for LSDs that has used different lentiviral
vectors, emphasizing gene promoters.

INTRODUCTION
Lysosomal storage diseases (LSDs) are a group of inherited metabolic
disorders caused by the deﬁciency of lysosomal enzyme activity (Table 1). As a result, the lysosome dysfunction accumulates undegraded
or partially degraded molecules, affecting the entire body. The clinical
outcome of patients in most LSDs affects neurological and peripheral
organs.1 Despite many attempts, most LSDs cannot be effectively
treated to date.2 Therapies for LSDs are based on the cross-correction
mechanism discovered more than 50 years ago. This mechanism is
based on the ability of the soluble enzyme to recognize the
mannose-6-phosphate receptor owing to the ligand present.3–5 In
conventional enzyme replacement therapy (ERT), the recombinant
enzyme could be delivered intravenously, but owing to enzyme
inability to cross the blood–brain barrier (BBB), different administration routes have been tested via intrathecal or intracerebroventricular
administration. Another approach is to modify enzymes to penetrate

the BBB via transferrin receptor.6,7 Although ERT is an available
treatment for some LSDs, there are several limitations compared
with ex vivo lentiviral-mediated gene therapy: (1) its half-life is short,
(2) the cost is expensive, (3) it has a limited impact on avascular tissues organ, and (4) weekly infusions are required for life.8
Potential therapy for LSDs is hematopoietic stem cell transplantation
(HSCT), where the cells from a healthy donor repopulate in the recipient patient and secrete enzymes within the periphery of the organism. During the HSCT process, the monocytes can cross the BBB,
differentiate into microglial cells within the brain, and mediate the
cross-correction.9 “HSCT could protect or ameliorate CNS damage
in some LSDs if it is conducted at an early stage; however, it still
does not correct CNS impairment in other diseases.” There is also a
risk of transplant rejection and immune reaction (graft-vs-host disease) to transplanted cells.10,11
In recent years, gene therapy has attracted more attention owing to its
potential use in single-gene diseases, including LSDs. Promising viral
gene therapy results on animal models have been observed with regards to safety and efﬁcacy.12 At present, the most promising vectors
for replacing missing genes are either adeno-associated viruses (AAV)
or lentiviruses (LV). Both of these viruses have advantages and drawbacks. The main disadvantage of AAV use is the low size capacity of
the transgene (approximately 4.5 kb). Another disadvantage is the
requirement for a proper serotype that recognizes target cells and tissues and does not trigger an immune response.13 Some patients have a
pre-existing immune response to AAV vectors in the form of vectorneutralizing antibodies.14 Other research conﬁrmed that 30% of
screened patients had pre-existing antibodies against the AAV8
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Table 1. LSDs and therapeutic management
Disease

Eponym

Action myoclonus

renal failure syndrome

Aspartylglucosaminuria

Defective enzyme5

Stored material

Standard of
care5

Gene therapy clinical trials

unidentiﬁed

Lysosomal integral membrane
protein (LIMP-2)

none

glycoproteins96

aspartoglucosaminidase

HSCT
HSCT

AAV GT (NCT00151216;
NCT01161576; NCT01414985)

95

Ceroid lipofuscinosis 1

Batten disease

palmitoyl-protein thioesterase 1
(PPT1)

Ceroid lipofuscinosis 2

late infantile neurona ceroid
lipofuscinosis (LINCL)

tripeptidyl peptidase

ERT

AAV GT (NCT00151216;
NCT01161576; NCT01414985)

Ceroid lipofuscinosis 3

juvenile neuronal ceroid
lipofuscinosis

lysosomal transmembrane
protein

none

AAV GT (NCT03770572)

Ceroid lipofuscinosis 4

Parry disease

cysteine string protein alpha
(CSPa)

none

Finnish variant of NCL

CLN-5

none

Ceroid lipofuscinosis 6

late-infantile/early juvenile NCL

transmembrane ER protein
CLN-6

none

Ceroid lipofuscinosis 7

late infantile variant

lysosomal membrane protein

none

Ceroid lipofuscinosis 8

–

protein CLN-8 (Subunit c of
mitochondrial ATP synthase)

none

Ceroid lipofuscinosis 9

–

lipofuscin97
Ceroid lipofuscinosis 5

unknown

none

Ceroid lipofuscinosis 10 –

cathepsin D

none

Ceroid lipofuscinosis 11 –

granulin precursor

none

juvenile parkinsonism–neuronal
Ceroid lipofuscinosis 12
ceroid lipofusciosis

cation-transporting ATPase
13A2

none

Ceroid lipofuscinosis 13 Kufs disease type B

cathepsin F

none

Ceroid lipofuscinosis 14 progressive myoclonic epilepsy

potassium channel
tetramerization domain
containing98

none

lipofuscin97

AAV GT (NCT02725580;
NCT04273243)

Cobalamin F-type
disease

–

cobalamin99

LMBD-1

none

Cystinosis

–

cystine55

cystinosis or CTNS

Cysteamine

LV GT (NCT03897361)

Danon disease

–

absence of lamp2
protein100

LAMP-2

none

AAV GT (NCT03882437)

Fabry disease

–

glycosphingolipids

a-galactosidase A

ERT

LV GT (NCT02800070,
NCT03454893); AAV GT
(NCT04519749; NCT04046224;
NCT04040049)

Farber
lipogranulomatosis

–

ceramide102

acid ceramidase

HSCT

Fucosidosis

–

Fucosylated
glycoconjugates103

a-l-fucosidase

HSCT

Galactosialidosis

–

galactosialidosis104

combined deﬁciency of
b-galactosidase and
neuraminidase

none

Gaucher disease (types I,
–
II, and III)

glucocerebroside105

b-glucocerebrosidase

ERT; PCT;
SSI; HSCT

LV GT (NCT04145037,
NCT00001234, NCT00004294);
AAV GT (NCT04836377)

GM1 Gangliosidosis

–

GM1 ganglioside106

b-galactosidase

HSCT

AAV GT (NCT04273269;
NCT03952637)

GM2 Gangliosidosis
type I

Sandhoff disease

GM2 ganglioside107

b-hexosaminidase B

PCT

AAV GT (NCT04798235,
NCT04669535)

101

(Continued on next page)
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Table 1. Continued
Disease

Eponym

GM2 Gangliosidosis

GM2 activator deﬁciency

GM2 Gangliosidosis
type I

Tay–Sachs disease

Globoid cell
leukodystrophy

Krabbe disease

Metachromatic
leukodystrophy

–

Defective enzyme5

Standard of
care5

GM2 ganglioside activator

none

b-hexosaminidase A

PCT; SSI

galactocerebroside109

galactocerebrosidase

HSCT

AAV GT (NCT04693598)

sulfatides110

arylsulfatase A

HSCT

LV GT (NCT02559830;
NCT03725670; NCT04283227;
NCT01560182; NCT03392987)

mucolipids111

Stored material
GM2 ganglioside108

Gene therapy clinical trials
AAV GT (NCT04669535)

Mucolipidosis I

sialidosis type I, II

a-acetyl neuraminidase

none

Mucolipidosis IV

–

cation channel mucolipin 1

none

Mucolipidosis type II
and III

I-cell disease

GlcNAc-1-phosphotransferase

none

MPS type I

Hurler; Hurler–Scheie or Scheie
syndrome

HS, dermatan sulfate

a-L-iduronidase

ERT; HSCT

LV GT (NCT03488394); AAV
GT (NCT03580083); ZFN
(NCT02702115); SB
(NCT04284254)

MPS type II

Hunter syndrome

HS, dermatan sulfate

2-iduronate sulfatase

ERT; HSCT

LV GT (NCT00004454); AAV
GT (NCT04571970;
NCT03566043; NCT04597385);
ZFN (NCT03041324)

MPS type IIIA

Sanﬁlippo syndrome type A

HS

N-sulfoglucosamine
sulfhydrolase

none;

LV GT (NCT04201405); AAV
GT (NCT04088734;
NCT04360265; NCT03612869;
NCT02716246)

MPS type IIIB

Sanﬁlippo syndrome type B

HS

a-N-acetylglucosaminidase

ERT

AAV GT (NCT03315182;
NCT04655911)

MPS type IIIC

Sanﬁlippo syndrome type C

HS

acetyl-CoA:a-glucosamine
acetyltransferase

none

MPS type IIID

Sanﬁlippo syndrome type D

HS

N-acetylglucosamine 6-sulfatase

none

MPS type IVA

Morquio syndrome type A

keratan sulfate,
chondroitin sulfate

N-acetylgalactosaminide 6sulfatase

HSCT; ERT

MPS type IVB

Morquio syndrome type B

keratan sulfate

b-galactosidase-1

none

MPS type VI

Maroteaux- Lamy syndrome

dermatan sulfate

N-acetylgalactosamine 4sulfatase

ERT; HSCT

MPS type VII

Sly syndrome

HS, dermatan sulfate,
chondroitin sulfate

b-glucuronidase

ERT; HSCT

MPS type IX

Natowicz syndrome

hyaluronan112

hyaluronidase-1

none

multiple sulfatases

none

acid sphingomyelinase

none

NPC1 or NPC2

SSI

Multiple sulfatase
deﬁciency

Austin disease

Niemann-Pick A and B

–

Niemann-Pick C

–

GAG and sulfatides

113

lipid114

Glycogen storage disease
Pompe disease
type II

glycogen115

acid maltase or acid alphaglucosidase

ERT

Schindler disease

Kanzaki disease

glycoproteins116

a-N-acetylgalactosaminidase

none

Sialic acid storage
disease

–

sialic acid

sialin

none

Wolman disease

–

cholesterol esters118

lysosomal acid lipase

HSCT

b-mannosidosis

–

b- mannosidose

b-mannosidase

none

117

AAV GT (NCT03173521)

LV GT (NCT03454893); AAV
GT (NCT02240407;
NCT03533673; NCT04174105;
NCT04093349)

AAV GT, AAV gene therapy; HSCT, hematopoietic stem cell therapy; SSI, speciﬁc substrate inhibition; PCT, pharmacological chaperone therapy; LV GT, lentiviral-mediated gene
therapy under clinical trial with modiﬁed hematopoietic stem cells; SB, sleeping beauty transposon; ZFN, genome editing by the zinc ﬁnger nuclease.
Clinical trials numbers were taken from clinicaltrials.gov (access date 8/3/2021).
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Figure 1. Three generations of lentiviral vectors
The first generation contained the nef, vif, vpu, and vpr genes—the HIV-specific accessory genes and the gag and pol genes necessary for the life cycle of the virus. Envelope
protein (env gene) is used as another element to extend tropism of LV, called pseudotyping of the virus.91 Pseudotyping of the virus could enhance the expression of
the transgene as the surface protein of the virus capsid can target cells.92 The commonly used envelope protein is vesicular stomatitis virus G protein (VSV-G), owing to the
recognition of ubiquitously expressed receptors present on many cells, allowing the infection of various cell types. The second generation of LVs does not contain
the accessory virulence factors. They still contain the transcription activator (tat gene) and the regulatory protein (rev gene). The third generation of LVs was created so that the
viral genome was divided into four expression cassettes: envelope protein, two packaging cassettes, and gene of interest expression cassettes to increase the expression
and safety. The genes necessary for the construction of the virus are found on the packaging cassette, where one plasmid vector contains the gag and pol genes, and the
other plasmid contains the rev gene. Additionally, the third generation of the virus lacks the tat gene, and its expression function is replaced by an upstream LTRs construct
that is continuously active.19 Moreover, to improve safety, a deletion in the 30 LTR was made to create self-inactivating (SIN) lentiviral vectors.91 poly(A), polyadenylation; RRE,
Rev-responsive element; c, required for packaging of the genomic tRNA; SIN, self-inactivating element; LTRs contains three elements: U3, R, and U5, in third generation
enhancer U3 in the 30 LTR is deleted

vector, and in most cases, cross-reactivity to AAV2 and AAV5 was
detected.15 Notably, antibodies against AAV can be detected at birth,
suggesting maternal antibody transmission to the newborns.16
LV vectors have a higher capacity for the potential gene (%15 kbp)
and broad tissue tropism that can be accomplished using various viral
envelopes.17 One of the signiﬁcant discoveries in LV is that these viruses infect both dividing and nondividing cells and integrate into the
host chromosome. Therefore, LV vectors display stable and longterm expression of the transcript. However, this could also be a disadvantage since they can activate oncogenes close to LV integration13 or
cause the silencing of genes necessary for cells. LVs include several
different viruses by genus: the simian immunodeﬁciency virus, human immunodeﬁciency viruses (HIV-1 and HIV-2), and diverse nonprimate LVs. The ﬁrst developed and most commonly used lentiviral
vector was based on HIV-1, which effectively transduces nondividing
cells.18 Three generations of HIV-1 based LVs have been produced
over the years owing to the biosafety concerns of using a highly infectious virus (Figure 1).19 Nevertheless, the HIV-1 backbone could be
modiﬁed further. Vectors can be created by combining two viruses,
fusing the backbone of one virus and expression element from the
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other virus,19 or deleting part of sequences from HIV-1 (SMPUR
vector) (Figure 2).20
Furthermore, a modulation of the transgene expression cassette could
be critical for clinical settings. Increased or decreased levels of the
transgene could be adjusted to clinical needs to reduce adverse effects
such as overexpression of the therapeutic gene.21 Yet, this is a multivariable problem between vector copy, integration site, and promoter
choice.22 The lentiviral vector expression cassette with the target
transgene can be modulated depending on the need. The essential
components of the lentiviral vector include enhancer/upstream promoter, promoter, the gene of interest, inverted terminal repeats/
LTR, and polyA signal sequence.23 Other frequently used cis-acting
elements are introns and post-transcriptional regulatory elements
(PREs) to ensure a high-level transgene expression.
PREs also protect the transgene from silencing. One of the most
widely used PREs is WPRE from Woodchuck hepatitis virus, where
the transgene expression increased 8.6-fold relative to a cassette
without WPRE in vitro.19 Another part of the expression cassette
that can increase the transgene expression is the polyadenylation
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Figure 2. Lentiviral vector backbone modifications
The SMPUR vector is absent in the self-inactivating sequences in the expression cassette and includes sequences that increase pro-viral integration. It includes sequences
from SV40, which can increase polyadenylation efficiency from the 30 LTR2620. There are differences in fusing the elements in pRRL, pRLL, pCCL, and pCLL. In pRRL, both
enhancer and promoter are from RSV virus U3 region joined to the R region of the long terminal repeats in HIV-1 virus. In pRLL, an enhancer from the RSV enhancer is joined
to the promoter region of HIV-1. In pCCL, both enhancer and promoter from the CMV are joined to the R region of HIV-1. In pCLL, only the CMV enhancer is joined to the
promoter region of the HIV-1.19 RSV, Rous sarcoma virus; SV40, simian virus 40.

(poly[A]) site of the transcript. It is crucial for mRNA transportation
from the nucleus and then increasing its stability and efﬁciency of
translation. The polyadenylation signal sequence has been placed upstream of the enhancer in the expression cassette to improve efﬁciency. When polyadenylation signal and WPRE elements were
compared in SV40, both improved transgene expression to a similar
level.23
LVs in gene therapy can be divided into two categories, depending
on the administration route, either in vivo and ex vivo. In the in vivo
route, the LV is introduced directly into the host by intravenous or
intrabrain administration. In contrast, the ex vivo approach takes
advantage of the virus-mediated transduction of the isolated
HSCs of the host cells and then a reintroduction of these modiﬁed
cells into the same patient.24 Preclinical studies using mouse
models need donor and recipient differentiation, because it is
impossible to isolate enough cells from the same mice to make
the transduction. Figure 3 describes the process of in vivo and
ex vivo gene therapy in the mouse model. Local brain administration of lentiviral vectors has shown broad and stable transgene
expression through different cells, transducing most brain cells in
animal experiments, such as neurons and astrocytes. LVs have
been used in many neurological diseases, and LSDs are potential
target applications.25
Selecting the proper promoter is crucial to obtaining effective
transgene production within the cells.26 The promoter is a major
cis-acting element found at the beginning of the gene to be transcribed. Attaching RNA polymerase to the binding site of the promoter activates the transcription of the desired gene. Promoters
dictate the overall strength of gene expression and direct tissue
or cell target speciﬁcity.23 During the last decade, different promoters, including both tissue-speciﬁc and housekeeping, have
been used to treat LSDs (Figure 4).

This review summarizes the promoters of lentiviral vectors used for
LSDs, and it will help to guide future experiments with lentiviral vector gene therapy.

PROMOTERS
Housekeeping promoters
Phosphoglycerate kinase promoter

Phosphoglycerate kinase (PGK) promoter has been widely tested for
transgene expression for a long time showing vigorous activity in
different kinds of tissues as murine embryonal stem27 or myeloid
cells, including mature neutrophils.28
MPS IIIA is one of the most common mucopolysaccharidoses
(MPS), caused by a deﬁciency of heparan N-sulfatase, resulting
in the accumulation of glycosaminoglycan (GAG), heparan sulfate
(HS). Among the ﬁrst use of lentiviral therapy in MPS, LV bearing
a transgene under the control of the PGK promoter was injected
intravenously into 5-week old-MPS IIIA mice. After 6 months of
treatment, the GAG content was decreased compared with untreated animals. Moreover, the weight of mice became normalized.
However, enzyme activity and vector copy number within organs
have not been checked.29
Direct intracerebral injection into neonatal Krabbe mice of an LV expressing the gene coding for the missing galactocerebrosidase under
the PGK promoter showed robust transduction of nerve cells with a
minimal inﬂammatory response. Enzymatic activity in the central
nervous system increased 8 days after injection. Direct administration
at an early stage of the disease led to partial degradation of the storage
material and increased the mouse lifespan. However, 6 months after
initiation of the therapy, it was noted that the LV genome was only
detected in the injection region of the brain.30 Similarly, the
maximum intensity of the vector copy number per cell was visible
at the LV injection,31 indicating that lentiviral vectors cannot spread
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ease) ex vivo gene therapy. Transgene expression was optimized by
adding miRNA to the expression cassette.35 The overexpression of
the galactocerebrosidase enzyme was shown to be toxic to the
HSCs.36 To regulate the expression of the enzyme, speciﬁc miRNA
has been identiﬁed (miR-126 and miR-130a). Incorporating the
miRNA and codon-optimized human enzyme cDNA into the expression cassette resulted in selective and increased enzyme activity within
the only transduced hematopoietic stem and progenitor cells compared
with untreated mice.36 Transplantation followed by virus transduction
of cells taken from mice showed that the missing enzyme activity
increased shortly after implanting the cells into the donor mice.
More prolonged survival and improved phenotype were noted in the
cell-transplanted mice compared with the untreated mice. A correlation between the vector copy number in the bone marrow isolated
from the mice and increased enzyme activity was noted. Enzyme activity in the brain, the most affected organ in Krabbe disease, was only
slightly increased without statistical signiﬁcance (4 ± 0.5 nmol/mg 
h) compared with untreated mice (undetected), suggesting that it could
correlate with the PGK promoter not being expressed explicitly in
brain.35 In this case, the added miRNA did not affect decreased expression, because the control vector (also with PGK) did not have higher
expression in the brain than the tested vector.35

Figure 3. Ex vivo and in vivo gene therapy in animal models
In ex vivo gene therapy, stem cells are isolated from the donor mice, transduced with
LV vector, and injected into recipient mice. In vivo gene therapy approach is a direct
administration of the virus to the brain (intraparenchymal, intracerebroventricular, or
intracisternal) or intravenously.93

throughout the brain after direct injection. In contrast, the AAV has
shown the ability to spread by axonal transport within the brain.32
One of the ﬁrst research with the PGK promoter in ex vivo LV treatment was conducted in the xenograft murine model of MPS VII. Peripheral blood CD34+ cells from MPSVII mice were transduced with
a LV vector expressing b-glucuronidase enzyme under PGK promoter.
Were injected 5- to 10-week-old mice with transduced cells after radiation conditioning. Enzyme activity was measured in the human cells
(10.8 ± 1.6%) in the bone marrow from animals. Vector copy number
in bone marrow 12 weeks after transplantation was 1–2 per positive
cell. After transplantation, lysosomal storage decreased in the liver.33
The PGK promoter also has been used in ex vivo lentiviral-mediated
therapy. MPS I mice were injected intravenously with transduced cells
with the lentiviral vector encoding the IDUA gene (or cDNA). After
6 months of therapy, GAG levels were normalized in urine and tissues
(liver, spleen, and kidneys). The enzyme activities in organs (liver,
spleen, kidney, heart, and brain) were higher than that in HSCT. Additionally, animal behavior in treated mice was improved with ex vivo
gene therapy, which was not noted in the mice that underwent
HSCT. Patients with MPS I suffer from progressive severe skeletal
dysplasia. The ex vivo lentiviral-mediated gene therapy has shown
improvement of skeletal dysplasia in MPS I mice.34 The PGK promoter
was also used in globoid cell leukodystrophy (also called Krabbe dis-
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One of the most common LSDs is Gaucher disease. Although patients
have many treatments available,5 patients can be unresponsive to ERT
or have problems ﬁnding a suitable HSCT donor. Lentiviral vector
therapy with transgene expression under the control of ubiquitous
PGK or macrophage-speciﬁc CD68 promoters has been tested in a
mouse model of Gaucher disease. After transduction of cells and
transplantation to mice, enzyme activity increased compared with
untreated mice, leading to the clearance of glucosylceramide and
reversal of phenotype in both tested promoters groups. The PGK promoter has shown a higher (2 ± 1 copies/cell) vector copy number in
bone marrow and higher enzyme expression levels compared with
untreated animals.37
Human clinical trials (NCT01560182, NCT04283227) with ex vivo
lentiviral-mediated therapy have been conducted in metachromatic
leukodystrophy, where neurological dysfunctions lead to a rapid progression of the disease, eventually causing death within a few years after the ﬁrst symptoms occur. Three presymptomatic patients have
been infused with LV-transduced cells expressing the ARSA enzyme
under the PGK promoter. These patients have shown stable expression of the enzyme throughout hematopoietic lineages and in cerebrospinal ﬂuid. Moreover, disease progression has not been seen,
even after the predicted age of symptom onset.38,39 Primary outcomes
from the second clinical trial (NCT04283227) indicate an increase in
enzyme activity in cerebrospinal ﬂuid as well as in neuronal metabolite ratio of N-acetyl-aspartate to creatine (https://www.clinicaltrials.
gov/ct2/show/NCT04283227 accessed July 13, 2021).
Cytomegalovirus promoter

Cytomegalovirus (CMV) promoter is another strong promoter with
housekeeping expression. It was tested in different tissues such as
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Figure 4. Lentiviral vector promoters used in LSDs (based on94)
Promoters can be divided into two groups depending on their expression site: tissue-specific (CD11b;75,119 ALB;120 TBG;72 MHC;121 MLC2v;122,123 cTnT;124,125) or
ubiquitous/housekeeping (CMV;126,127 PGK;27,127,128 EF-1a;43,127 MND;57 MCU3;58,59 SFFV;129,130; CBh;131). If the recombinant gene product is to be secreted in all cell
types, then housekeeping/ubiquitous promoters are preferable. Conversely, tissue-specific promoters can be used to express the recombinant gene product in one specific
tissue, such as neurons or astrocytes, to treat central nervous system damage.23 Moreover, syntenic promoters, which are chimeric promoters composed of natural
promoters, can be produced to optimize the transgene expression and enhance the precision of the infection.83

myeloid cells, including mature neutrophils showing vigorous activity
in lentiviral gene transduction.28
LV bearing the IDUA gene under the control of the CMV promoter
was administered into MPS I mice by direct tail injection. The highest
concentrations of IDUA were found in the liver and spleen. Polymerase chain reaction analysis demonstrated that the integration of the
viral genome took place only in the liver and spleen, which means
that the cross-correction mechanism carried out the reduction of
GAG levels in the remaining tissues. During long-term analysis
(6 months), the presence of antienzyme antibodies and decreased
enzyme activity, as well as decreased vector integration, were noted.
Probably owing to a substantial immune response, the transgene
was no longer present after long-term treatment.40
In contrast, in Pompe disease, owing to enzyme acid a-glucosidase
deﬁciency, glycogen accumulates mainly in the heart and skeletal
muscles, resulting in devastating symptoms. The direct intravenous
administration of CMV-LV vector to newborn knockout Pompe disease mice led to transgene expression in the liver and heart for up to
24 weeks. A decrease in the glycogen level was seen in skeletal and cardiac muscles after a single injection without an immune reaction in
most 41 mice44 (out of 43 mice, 3 had antibodies against enzyme).41
The choice of the promoter or determination of a particular sequence
included in the expression cassette was the subject of extensive analysis performed by Ou et al. (2016).42 Four promoters have been
compared in MPS I mice: PGK, EF-1alpha, CMV, and the synthetic
CE promoter (composed of the enhancer of the murine CMV immediate-early gene and human EF-1a promoter) with different WPRE
variants. All tested promoters decreased GAG levels in the liver,
whereas GAG levels were decrease with only CE and particular
WPRE modiﬁcation in the brain and spleen. Similarly, enzyme activ-

ity was expressed in liver in all of the tested promoters, while the
enzyme activity in spleen and brain signiﬁcantly increased only by
CE promoter. Additionally, this promoter provided the lowest transgene frequency in the gonads, which is important in using LVs to integrate into the host genome, reducing the potential germline transmission.42 When comparing four variants of the WPRE in the CE
promoter, one of them has the highest expression, suggesting that
promoters are less important in the expression than additional transcription regulators.42
Elongation factor-1a promoter

Eukaryotic translation elongation factor 1a promoter is a strong
native promoter, expressed in almost all kinds of mammalian cells.43
One of the most used housekeeping promoters in LSDs.
Although LV is an effective tool in disease correction, its integration
ability could lead to serious adverse effects by oncogene activation.44
An analysis of the distribution of integration sites of the LV has been
performed in a metachromatic leukodystrophy mouse model. Fourweek-old mice were intracranially injected with LV expressing the
ARSA enzyme under the EF1-a promoter. The LV integration sites
proﬁle was measured in the murine brain ependymal cells. There
was preferable integration within tandem repeats (e.g., satellite
DNA). Moreover, host non–B DNA motifs were identiﬁed as a
possible factor contributing to the LV integration sites. Most important, none of the integration sites were detected in or within 50 kb to
known oncogenes.45 A comparison of two different strategies of vector delivery (either by intravenous injection or by ventricular infusion) was assessed in 6-week-old MPS VII mice. The same vector
has been used in both cases, with the EF-1a promoter.46 After
7 months from an intravenous injection, vector delivery proved effective in restoring enzyme levels in the liver. Moreover, most somatic
and brain pathology was corrected with improved behavior. However,
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intraventricular vector delivery reduced lysosomal storage in the central nervous system, biochemically and histologically normalizing
brain pathology and mouse behavior. Additionally, a reduction of
lysosomal storage was evident in the eyes of mice. Ventricular vector
delivery was more effective in brain-related disease outcomes.46
In another study, when a lentiviral vector with the same promoter
was administrated into two different MPS VII newborn mice, the
enzyme level was normalized after 12 and 18 months of the therapy.
Elevated enzyme levels resulted in lysosomal storage reduction in the
liver, spleen, kidney, and heart. Moreover, bone mineral volume
decreased in both mouse models with improving behavioral analysis.
The signiﬁcantly prolonged life span of the mice was also observed
after administration of LV in neonatal mice.47 In contrast, MPS VII
mice fully manifesting skeletal symptoms have been administered
with a lentiviral vector expressing b-glucuronidase, driven by the
EF-1a promoter. After 2 months from the administration, skeletal
pathology has been reversed.48 Direct brain delivery has been used
for lentiviral gene therapy in MPS IIIA mice. Vectors bearing the
transgenes were delivered to the cerebral lateral ventricles. Two lentiviral vectors were tested in that study, and in both cases, EF-1a
gene promoter was used.31 The difference between them was that
one expressed codon-optimized murine heparan N-sulfatase, while
the other expressed both heparan N-sulfatase and sulfatase modifying factor-1. After 6 months from the intraventricular injection,
the behavior was improved, and bladder distension was not seen
in any treated mice. When the two vectors were compared, the simple one was more effective in increasing enzyme expression in the
brain. This also translated into a reduction in ganglioside and elevation of lysosomal b-hexosaminidase levels.31 The most concerning
issues in delivering the missing enzyme are those for the brain
and bone. Most LSDs reveal dysfunctions of these organs, leading
to a decline in the activity of daily living. Disability-related bone
damage affects children with MPS I, II, IV, and VII, mucolipidosis
types II and III, and Gaucher disease. Clinical symptoms may vary
between LSDs and even between patients. Some patients are asymptomatic and without radiographic evidence of bone pathology. In
contrast, others have obvious bone crises, short statures with typical
dysostosis multiplex symptoms, bone deformations, or osteopetrosis
with neurotic breaks.49
Farber disease is one of the rare lysosomal diseases with lipid accumulation owing to ceramidase deﬁciency. Ex vivo gene therapy with
EF1-1a promoter was tested in nonhuman primates. To track the
expression of the enzyme CD25 promoter, speciﬁc for T cells, was
included in the expression cassette.
A preclinical study on nonhuman primates was conducted for Farber
disease with a lentiviral vector expressing the gene coding for ceramidase from the EF-1a promoter, with CD25 promoter included in the
cassette to track expression,50 speciﬁc for T cells.51 Peripheral blood
was collected from animals, transduced with the virus, and reintroduced to the same animals, tracking therapy efﬁciency for one year.
The transduced vector was found in bone marrow and peripheral
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blood (PB) cells with decreased storage material in PB, liver, and
spleen.50
In Fabry disease, EF-1a promoter has been used as well. Bone marrow
mononuclear cells were transduced with a lentiviral vector encoding
the human alpha-galactosidase A gene (or cDNA) and were injected
into the Fabry mouse model. Increased enzyme activity and reduction
of the accumulated substrate were observed 20 weeks after cell transplantation.52 A more recent study also used the same promoter in
the Fabry disease mouse model, leading to the increased level of the
enzyme and a reduced substrate 6 months after transplantation. In
this study, the authors also tested LV transduction of CD34+ hematopoietic stem cells isolated from Fabry disease patients with a successful
increase of enzyme activity. After mouse engraftment with LV-transduced CD34+ cells, the enzyme level was increased, and lipid storage
material accumulation decreased.53 Currently, this approach is under
clinical investigation with EF1-a promoter (NCT02800070) for Fabry
disease. Five male patients with the type 1 phenotype have been evaluated for safety and efﬁciency of the treatment after up to 1,000 days after the infusion of the transduced cells. There were no serious adverse
effects of the study, where only two patients could be potentially related
to the investigational product (nausea, grade 1; cough, grade 2). After
1 week of treatment, all patients produced the normal level of the
enzyme with a decrease over time. Reduction of accumulated substrates
has been noticed in plasma and urine of the patients.
Moreover, the anti–a-galactosidase A antibody level increased in one
of the patients and then rapidly decreased. However, only one patient
was treated with gene therapy exclusively and sustained low levels of
accumulated substrates in plasma and urine owing to gene therapy
only.54 The other four patients resumed ERT 1 month after transplantation. Another ex vivo lentiviral-mediated gene therapy is also under
investigation in a clinical trial in patients with Fabry disease
(NCT03454893), but the type of promoter is not being disclosed in
this case.
In cystinosis, cystine is accumulated in all tissues, mostly in kidneys,
and cysteamine is the only available therapy.55 Nevertheless, gene therapy with transduced HSCT (ex vivo) has been tested in a mouse model
of cystinosis with EF-1a promoter. Intravenous treatment with transduced cells decreased accumulated material in every tissue, improving
kidney function as well. Moreover, the correlation between transgene
expression in PB and tissues was shown, which could be helpful for patient treatment, suggesting a cross-correction mechanism.56
MND vector

The MND is a synthetic promoter that contains two elements: the U3
region of a modiﬁed Moloney murine leukemia retrovirus with long
terminal repeats and an enhancer from the myeloproliferative sarcoma virus. It is a constitutive promoter with high expression in
the hematopoietic system.57 Either neonatal, 1–2 days old, or 8week-old MPS I mice have been intravenously injected with a lentiviral vector expressing the IDUA enzyme under the MND synthetic
promoter. At 5 months old, mice have been euthanized. It has been
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noted that, if lentiviral-mediated gene therapy is given early enough,
IDUA activity also appears in the brain of MPS I mice, with increased
neuron transduction.
Additionally, a reduction in GAG levels, prevention of the appearance of
skeletal abnormalities, and increased life expectancy have been noted in
neonatal mice.20 Furthermore, the MND promoter has been modiﬁed
with the CMV TATA sequence to activate and sustain expression in hematopoietic human stem cells. Part of the MND was used for the internal promoter that is replaced with the TATA sequence of the human
CMV promoter, which is called the MCU3 promoter.58,59 LVs with
either MND or MCU3 promoters are not cell-speciﬁc promoters, but
can be widely introduced into nondividing and dividing cells. One of
the approaches presented combination therapy of two different vectors
expressing the NAGLU enzyme in MPSIIIB neonatal mice. AAV vector
was injected intracranially while LV with MND promoter was injected
intravenously. In the case of this combination therapy, we could see an
improvement in behavioral analysis (motor function and hearing) as
well as an increased lifespan of the animals. Brain enzyme activity
was not detected in lentiviral gene therapy only, increased only in combination therapy of both viruses. Systematic enzyme activity in LV treatment was increased, while with combination therapy, this activity
decreased (liver, 0.55-fold normal activity LV alone; 0.1-fold normal activity in combination treatment with AAV).60 This could be correlated
with increased antibodies against the enzyme, which was not measured
in these experiments.61
Ex vivo lentiviral-mediated gene therapy with the MCU3 promoter
was administered into MPS II mice, where brain and bone are mostly
affected. Consequently, neurological and peripheral GAG accumulation was corrected.62 They have not mentioned bone alternation where
the skeletal system is affected in MPS II disease.63 In contrast, another
study investigated bone pathology in MPS II with the same LV vector.64 This therapy reduced bone GAG accumulation, improving
bone volume, density, strength, and trabecular number. Nevertheless,
in that study, irradiation was used for myeloablation, normally
affecting bone complications. The authors suggested that irradiation
did not affect bone formation, resorption parameters, and mineral
density in the diaphysis edge, evaluated by micro-computed tomography scans.64 Different preconditioning doses with irradiation were
tested in MPS II mice as the intense irradiation could effectively lead
to bone complications, a high mortality rate, and morbidity.64 Three
different doses were tested: low dose, low-dose irradiation plus an
anti–c-kit monoclonal antibody, and high dose. The iduronate-2-sulfatase (IDS) activity was high in all peripheral tissues with a robust
decrease in GAG accumulation no matter what dose was used.
Notably, animal behavior was improved only at the highest dose,
and the storage material was reduced in the brain, indicating how
important it is to precondition the efﬁcient engraftment of the modiﬁed cells.65 It is noted that there could be a correlation between the
choice of the promoter and irradiation as the myeloablation method.
Irradiation could activate speciﬁc transcriptional control elements
within promoters affecting increased transgene expression through
radiation-induced promoters.66–68 This approach was tested in cancer

cell gene therapy for early growth response 1 (Egr1) gene promoter,
where radiation resulted in the response of transcriptional enhancers.69 However, in the discussed research, this theory has not
been tested.
Spleen focus-forming virus promoter

The spleen focus-forming virus (SFFV) promoter was used in ex vivo
lentiviral-mediated gene therapy to treat MPS IIIA mice.9 In this
study, the donors of stem cells were derived from either wild-type
(WT) mice or MPS IIIA mice, further transduced with the lentiviral
vector bearing the gene for the missing enzyme (LV-WT-HSCT or
LV-IIIA-HSCT), and injected into MPS IIIA mice. These LVHSCT–treated groups were compared with the traditional transplantation group (WT-HSCT). Both of the LV-transduced groups had
effective engraftment within the donor, reaching more than 88%.
Only the LV-WT-HSCT experimental group corrected the behavior
of the MPS IIIA mice. The brain enzyme activity in LV-WT-HSCT
mice was detected up to 10% of WT mouse level, and ganglioside
and HS levels were reduced. MPS IIIA-LV transduced or WT-HSCT
mice have not shown a signiﬁcant improvement in animal behavior.
Neuroinﬂammation and GM2 gangliosides were reduced, but HS
levels remained elevated. This ﬁnding suggests that HS storage has
a more signiﬁcant impact on neuropathology than neuroinﬂammation as the mouse behavior was not changed.9
In the latest study, the same promoter has been used to treat mice with
Pompe disease.70 ERT is available for Pompe disease. However, onehalf of the patients with Pompe disease die before the age of 3 years
despite ERT. Previously, the same group using this promoter with
ex vivo lentiviral-mediated therapy has shown an overexpression of
the enzyme and decreased the accumulated glycogen levels in the
heart, diaphragm, spleen, and liver. Improvements in cardiac and respiratory function, skeletal muscle strength, and locomotor behavior
were observed as well. In this study, the donor cells were from male
mice while female recipient mice are different experimental models
for ex vivo gene therapy.71 The same experimental design with male
mice as a donor and female mice as a recipient in ex vivo gene therapy
was recently published. Lentiviral vector cassette expression also
included SFFV promoter; the difference was the optimization of the
open frame of the enzyme for improved expression included Kozak
sequence and an additional TGA stop codon. After 12 months of
treatment, a near normalization of glycogen level was observed in
heart muscles with complete locomotor behavior improvement.
Even though glycogen accumulates in the brain of patients with
Pompe disease, there are no prominent neurological symptoms.
However, this accumulation could increase the severity of other
symptoms like respiratory insufﬁciency and skeletal dysfunctions.
The reduction of accumulated glycogen in the brain was visible
with increased enzyme levels in microglia and the enzyme expression
in all treated astrocytes.
Moreover, this particular research was the only one that checked the
integration site of the lentiviral vector within the genome from all of
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the reviewed articles. Because LVs could be randomly integrated
throughout the genome, activating oncogenes, this research is significant. They did not observe any preference for integration near protooncogenes.70
Tissue-specific promoters

A tissue-speciﬁc promoter can be used to transduce speciﬁc cells or
tissues directly. One study compared different promoters, such as
the thyroxine-binding globulin (TBG) and other promoters. The activities of six promoters (CMV, EF1a, PGK, apolipoprotein E [apoE],
TBG, and cytochrome P450 2  101 [CYP2E1]) were compared by
introducing a transgene via a LV-mediated delivery system in the
liver. The TBG promoter revealed high activity; its expression was
less strong than the ubiquitous CMV and EF1a promoters, while it
was more robust than PGK, ApoE, and CYP2E1 promoters.72 Thus,
this study showed promise for tissue-speciﬁc promoters, at least for
liver transduction.
Liver-specific promoters

One way to efﬁciently express a transgene in gene therapy is to use the
liver as a distributor of the missing enzyme. Owing to the crosscorrection effect of lysosomal enzymes, this type of gene therapy targeting may be effective in the case of LSDs. When conducting a gene
therapy study, the liver is the organ with the highest expression of the
enzyme.5
A reduction of antibodies against the IDUA enzyme in the brain
was noticed, and levels of ganglioside and lysosomal b-hexosaminidase were reduced after 6 months of treatment with a construct
bearing the liver-speciﬁc promoter.31 In other studies, the albumin
gene promoter, a hepatocyte-speciﬁc promoter in the liver, was
used. After one month of treatment of 8- to 10-week-old MPS I
mice, the IDUA enzyme was active in the liver and spleen. In addition, only a 1% increase of enzyme activity could reduce GAG
levels in visceral organs such as the kidneys, heart, and lungs.
The results do not include brain GAG levels and enzyme activity,
although the brain is the most affected in patients with MPS I.40
Nevertheless, in one of the newest studies for Fabry disease, a tissue-speciﬁc promoter that targets the liver was used with the AAV
vector, not the lentiviral one, resulting in the supraphysiological
enzyme level in plasma up to 1,061-fold of WT level and correction of lysosomal storage pathology in visceral organs, such as
the liver, kidney, heart, and spleen.73

material has been observed in heart without notable differences between promoters.74
Myeloid-specific CD11b promoter

The CD11b promoter myeloid speciﬁcity seems to be the best in hematopoietic stem cell therapy. After the introduction into the patient,
cells ﬁrst differentiate into macrophages, and in the brain, into
myeloid cells.75 In recent years, ex vivo lentiviral-mediated gene therapy with CD11b has been used in many LSDs, including MPS II,76
IIIA,77,78 IIIB,79 all of which are characterized by damage to the central nervous system.
During the ex vivo study, MPS IIIA mice were treated with the vector
bearing the SGSH gene under the control of the ubiquitous PGK promoter and the myeloid-speciﬁc CD11b promoter. Both constructs expressed the missing enzyme.77 Previously, the same group noted a
partial improvement in the neuropathology in MPS IIIA mice with
autologous LV-HSC gene therapy, where the expression of the
missing enzyme was under the control of the SFFV promoter.9 However, owing to the insufﬁcient enzyme activity in the brain, they
decided to combine it with the CD11b promoter, speciﬁcally targeting
myeloid cells, which differentiate into microglial cells. As a result, the
construct increased the expression of the missing enzyme in the brain.
After 8 months of gene therapy, the CD11b promoter showed a higher
level expression of the SGSH gene in the brain than the PGK promoter. The authors have also demonstrated the normalization of animal behavior, the GAG level in the brain, and neuroinﬂammation in
the brain. The PGK promoter was only partially able to correct neuropathology without affecting animal behavior. However, both promoters caused the higher expression of the recombinant gene in
bone marrow than untreated mice.77

Cardiac-specific promoters

The same approach was applied to MPS IIIB mice with ex vivo lentiviral-mediated gene therapy with the CD11b promoter, ensuring the
NAGLU enzyme expression, compared with NAGLU containing a
C-terminal fusion to insulin growth factor 2 (IGFII).79 Direct intracerebroventricular delivery of the missing enzyme fused to IGFII
improved enzyme uptake of cells, as IGFII binds to the mannose-6phosphate receptor in MPS IIIB mice.80 After 8 months of treatment
with LV-NAGLU, the enzyme was signiﬁcantly increased with both
vectors, either with IGFII or without. LV-NAGLU-IGFII–treated
mice have shown limited enzyme secretion from engrafted macrophages in the brain, mimicking an in vitro experiment where LV-NAGLU-IGFII–treated cells did not secrete enzyme into the culture
media.79

Depending on which organ is affected, different tissue-speciﬁc promoters have been tested. In Fabry disease, cardiac manifestation is
one of the most severe symptoms, as lipid material is also stored in
the heart. Direct intravenous injection of the lentiviral vector in
neonatal Fabry disease mice has been made, comparing four promoters. Three of them were myocardial-speciﬁc promoters: myosin
heavy chain, myosin light chain, and cardiac troponin T, and the
fourth was the ubiquitous EF-1a promoter. After 10 weeks, enzyme
levels in serum increased, and 18 weeks later, some decrease in storage

As ex vivo lentiviral-mediated gene therapy with CD11b promoter has
been successful in MPS IIIA,77 IIIB,79 and MPS II mice,76 before clinical trial, preclinical safety and efﬁciency of the lentiviral vector have
been evaluated for the treatment of MPS IIIA.81 Autologous HSCT
gene therapy procedure starts with blood collection from the patient,
and then CD34+ cells are isolated, transduced with LV, and reintroduced into the patient.82 Accordingly, CD34+ cells, isolated from
blood, were transduced with a LV expressing SGSH under control
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of the CD11b promoter. After optimizing the transduction conditions
and the cryopreservation of CD34+ cells, biodistribution and genotoxicity were investigated in the mouse model. Effective transplantation and biodistribution without vector transmission to the germline
cells have been reported, which is particularly important in the case of
LVs.81
In all of the previous studies, the gene delivered by a lentiviral vector
encoded the enzyme deﬁcient in the disease. Alternatively, a lentiviral
vector bearing the gene for an IL-1 receptor antagonist under control
of the CD11b promoter was tested in MPS IIIA mice. The concept of
this research was based on neuroinﬂammation as a possible cause of
behavioral and cognitive disturbances. IL-1 receptor antagonist overexpression led to the receptor blockade that reduced gliosis and
behavioral disturbances in mice.78
A clinical trial with a lentiviral vector expressing the missing enzyme
gene from the CD11b tissue-speciﬁc promoter with autologous
CD34+ HSCT in MPS IIIA patients is ongoing (NCT04201405).
This clinical trial started in January 2020, intending to enroll ﬁve patients (R3 and %24 months of age) without any previous treatment,
with a time frame of up to 3 years for the measurement of safety and
efﬁcacy.

CONCLUSIONS AND FUTURE DIRECTIONS
Various researches and achievements on ex vivo lentiviral-mediated
gene therapy have been performed on synthetic promoters (MND,
MCU3 promoters).62,64,65 Synthetic promoters comprise the leading
promoter with an enhancer (cis-acting element) that is binding sites
for transcription factors. They have more advantage over native promoters as the expression could be modulated, with where to express,
when, and how much. Although the native promoter has the correct
pattern of expression, it is not recommended to modify it.83 For this
reason, the native promoters are tested initially, where their expression could be regulated by different factors, such as codon optimization or adding the element like WPRE elements or miRNA.35,84
A recent cancer incidence in two patients from clinical trials of lentiviral-mediated gene therapy (called Zynteglo) on sickle cell disease
has been reported. Subsequently, the clinical trial has been suspended
(NCT02140554). This trial has three treatment cohort groups, depending on the lentiviral vector manufacturing process to increase
vector copy number and engraftment potential. One sickle cell disease
patient treated for more than 5 years was diagnosed with acute
myeloid leukemia in an experimental group treated with bone
marrow isolated and LV-transduced cells. Moreover, the second patient in this clinical trial was diagnosed with myelodysplastic syndrome from another experimental group treated with cells collected
from PB after mobilization with plerixafor and LV-transduction.
Gene therapy with Zynteglo was already approved to treat beta-thalassemia in 2019 in the European Union. Zynteglo contains a lentiviral
vector encoding the human b-globin gene under the internal
erythroid-speciﬁc promoter.85,86 Both the US Food and Drug Administration and European Medicines Agency investigated the cause of

the cancer incidence. One of the potential contributory factors in
sickle cell disease could be the increased potential for leukemia.87
The solution to this problem may be nonintegrating LVs, which will
increase the safety of this kind of gene therapy.88 LVs that do not integrate into the host genome lack viral integrase enzymes by introducing a mutation in the packaging vector. Thus, the integration of
LV is blocked. Consequently, they reside in the form of episomal transcriptionally active DNA and enables the LV vector to express the
gene product.89 Nonintegrating LVs have lower transgene expression
levels compared with integrating LV owing to their episomal structure. These LVs form nucleosomes that lead to chromatic silencing
associated with histone modiﬁcation in this chromatin structure.90
With a higher capacity for transgene and elimination of potential
mutagenesis associated with integration, nonintegrated LVs have a
potential advantage over AAV vectors. Additionally, a portion of
the methodologies focuses on (1) increasing transgene expression,
(2) constructing fused genes, and (3) adding tags to transgene protein
in the expression cassette and to allow the transgene to deliver to the
target tissue efﬁciently. In one of the recent studies, not only myeloidspeciﬁc CD11b promoter, but also ApoEII targeting brain receptors
were used, leading to complete normalization of brain pathology
and behavior in MPS II mice after ex vivo lentiviral-mediated gene
therapy. Furthermore, enzyme activity was also higher in plasma
when comparing with vectors without ApoEII modiﬁcation, suggesting that the vector is taken up by both HS/ApoE-dependent receptors
and mannose-6-phosphate receptors in the brain.76 Delivering the
missing enzyme through gene therapy is a promising approach for
LSDs. Gene therapy needs optimization in dose, time of delivery,
and promoter-driven expression. Throughout the years, several promoters have been used in ex vivo lentiviral-mediated gene therapy of
LSDs. Vectors used in the ex vivo approach have a higher vector copy
number than in in vivo gene therapy (Table 2). Clinical trials with
ex vivo lentiviral-mediated gene therapy provide promising results
with increased transgene expression. Choosing an appropriate promoter is crucial for obtaining the desirable effects of lentiviral gene
therapy. The proper choice depends on the disease, target tissue,
and organs. In some cases, a combination of promoters or the construction of fused and engineered promoters might give the best results. Based on the collected data we can conclude that tissue-speciﬁc
promoters are not as good as the ubiquitous promoters. In clinical trials ubiquitous promoters (PGK, EF1-a) have promising results so far
(NCT01560182, NCT04283227, NCT02800070). Further studies
must construct effective systems to deliver and express desired genes
into patients suffering from LSDs.

METHODS
Medical Subject Headings were applied for the selection of articles
in this review process. In PubMed search, we have used the keywords of “lysosomal storage disease, LV, and gene therapy”; “lentivirus, gene therapy, and lysosomes”; “ex vivo gene therapy and
lysosomal storage disease”; and “hematopoietic stem cell gene
therapy and lysosomal storage disease” with time selection ﬁlter
(2005–2020). We were focusing our research on preclinical
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Disease/
Promoter age

Vector copy number/cell
Time

ADM Dose

Liver

Spleen

Heart

Kidney

Brain

0.002 ± 0.001

0.0007 ± 0.0001 0.008 ± 0.0001

Lung

BM

WBC

–

–

–

Ref.

In vivo
MND

MPS I
1–2 d

5 mo

IV

1.65  1011 TU/kg 0.045 ± 0.01

0.01 ± 0.001

MND

MPS I
2 mo

5 mo

IV

6.88  109 TU/kg

0.01 ± 0.001

0.003 ± 0.0001 0.0007 ± 0.0001 0.0002 ± 0.0001 ND

–

–

–

ALB

MPS I
1 mo
2.0–2.5 mo

IV

0.6  109 TU/kg

0.125 ± 0.01

0.24 ± 0.01

–

–

–

–

–

–

ALB

MPS I
6 mo
2.0–2.5 mo

IV

0.6  109 TU/kg

0.2 ± 0.01

0.25 ± 0.003

–

–

–

–

–

–

CMV

MPS I
1 mo
2.0–2.5 mo

IV

0.6  109 TU/kg

0.075 ± 0.0001 0.2 ± 0.01

–

–

–

–

–

–

CMV

MPS I
6 mo
2.0–2.5 mo

IV

0.6  109 TU/kg

ND

ND

–

–

–

–

–

–

CMV

MPS I
1 mo
2.0–2.5 mo

IV

1.2  108 TU/mL

0.074 ± 0.018

0.83 ± 0.10

–

–

–

–

–

–

CMV

MPS I
6 mo
2.0–2.5 mo

IV

1.2  108 TU/mL

0.0022 ± 0.003 0.0026 ± 0.001 –

–

–

–

–

–

CMV

Pompe
1–2 d

6 mo

IV

NP

0.17 ± 0.035

0.095 ± 0.03

–

–

–

–

–

PGK

MPS I
1–2 d

1 mo

IV

1  107 TU/g

0.026 ± 0.0064 0.02 ± 0.008

–

–

0.0025 ± 0.0016 –

–

–

CE

MPS I
1–2 d

1 mo

IV

1  107 TU/g

0.049 ± 0.025

0.015 ± 0.076

–

–

0.0006 ± 0.0002 –

–

–

EF-1a

MPS I
1–2 d

1 mo

IV

1  107 TU/g

0.098 ± 0.033

0.037 ± 0.001

–

–

0.0024 ± 0.0009 –

–

–

EF-1a

MPS VII
1 mo

6-7 mo IV

0.3  109 TU

0.75 ± 0.19

0.11 ± 0.04

–

0.01 ± 0.004

–

0.01 ± 0.02

–

–

EF-1a

MPS VII
1 mo

6–7
mo

ICV

1.2  107 TU

0.01 ± 0.01

0.004 ± 0.0004 –

ND

–

0.01 ± 0.001

–

–

EF-1a

MPS VII
1–2 d

12 mo

IV

2.1  106 TU

0.8 ± 0.1

0.11 ± 0.5

0.01 ± 0.001

0.07 ± 0.02

0.01 ± 0.001

0.075 ± 0.02

–

–

Derrick-Roberts
et al.47

EF-1a

MPS VII
4 mo

2 mo

IV

2  107 TU/mL

0.2 ± 0.1

0.2 ± 0.1

0.01 ± 0.001

0.0005 ± 0.0001 0.0005 ± 0.0001 0.0025 ± 0.0001 –

–

Derrick-Roberts
et al.48

EF-1a

MPS IIIA
6 mo
1.5–1.6 mo

ICV

NP

–

–

–

–

–

McIntyre et al.31

Kobayashi et al.20

di Domenico et al.40

–

Kyosen et al.41

Ou et al.42

Bielicki et al.46

1.38 ± 0.94

–

–

(Continued on next page)
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Table 2. Promoters used in lentiviral gene therapy in preclinical mouse models

Disease/
Promoter age

Vector copy number/cell
Time

ADM Dose

Liver

Spleen

Heart

Kidney

Brain

Lung

BM

WBC

Ref.

0.23 ± 0.01 Langford-Smith et al.9

Ex vivo

Molecular Therapy: Methods & Clinical Development Vol. 24 March 2022

SFFV

MPS IIIA
2 mo

4 mo

IV

2.5  105 cellsa

–

–

–

–

–

–

–

SFFV

Pompe
1.5–3 mo

7 mo

IV

5105 cells

–

–

–

–

–

–

3.65 ± 1.8 –

van Til et al.71

SFFV

Pompe
12 mo
1.5–2.0 mo

IV

5105 cells

–

3.5 ± 1.3

–

–

–

–

–

–

Stok et al.70

CD68

Gaucher
5–8 mo

1 mo

IV

NP

–

–

–

–

–

–

1.2 ± 0.5

–

PGK

Gaucher
5–8 mo

1 mo

IV

NP

–

–

–

–

–

–

2±1

–

PGK

MPS IIIA
2 mo

6 mo

IV

NP

–

–

–

–

–

–

–

0.5 ± 0.3

CD11b

MPS IIIA
2 mo

6 mo

IV

NP

–

–

–

–

–

CD11b

MPS II
4 mo
1.5–2.0 mo

IV

3–4105 cells

–

1.5 ± 1

–

–

0.0002 ± 0.0001 –

CD11b

MPS IIIA
3 mo
1.5–2.0 mo

IV

3105 cells

–

–

–

–

ND

CD11b

MPS IIIA
4 mo
1.5–2.0 mo

IV

3105 cells

1 ± 0.5

2 ± 0.5

–

–

CD11b

MPS IIIB
2 mo

6 mo

IV

3  105 cells

0.5 ± 0.25

5 ± 1.5

–

MCU3

MPS II
6 mo
2.0–2.5 mo

IV

2106 cells

0.045 ± 0.02

–

MCU3

MPS II
2 mo

3 mo

IV

1.25106 cells

0.098 ± 0.001

MCU3

MPS II
2 mo

6 mo

IV

EF-1a

Fabry
3 mo
2.0–3.7 mo

EF-1a

Fabry
6 mo
2.0–3.7 mo

Dahl et al.37

Sergijenko et al.77
–

–

1.2 ± 0.5

2±1

1 ± 0.5

Gleitz et al.76

–

0.4 ± 0.1

0.55 ± 0.1

Ellison et al.81

0.25 ± 0.01

–

1.5 ± 0.5

2 ± 0.5

Parker et al.78

–

0.025 ± 0.01

–

1.5 ± 0.5

2.5 ± 1

Holley et al.79

–

–

0.0063 ± 0.001

–

–

–

Wakabayashi et al.62

1.131 ± 0.5

–

–

0.005 ± 0.001

–

–

–

Wada et al.64

6.6 ± 0.8105 cells 0.04 ± 0.01

0.7 ± 0.01

1.2 ± 0.3

0.03 ± 0.01

0.03 ± 0.001

4±1

–

3±1

Miwa et al.65

IV

1  106 cells

0.05 ± 0.01

0.275 ± 0.05

0.095 ± 0.05

0.025 ± 0.01

–

–

–

–

IV

1  106 cells

0.075 ± 0.01

0.225 ± 0.05

0.085 ± 0.1

0.035 ± 0.1

–

–

–

–

Huang et al.53

ADM, administration; BM, bone marrow; ICV, intracerebroventricular; IV, intravenous; ND, not detectable; NP, information not provided; WBC, White blood cells.
Mouse hematopoietic stem cell transduced with a lentiviral vector.

a
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experimental articles. We have also searched the clinical trials via
https://clinicaltrials.gov/.

14. Zaiss, A., and Muruve, D. (2005). Immune responses to adeno-associated virus vectors. Curr. Gene Ther. 5, 323–331.
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